AH Europe 2019 | Kisaco Research
Investment, Innovation and M&A
200 Aldersgate, St. Pauls, London, UK
26-27 February, 2019
Highlights
The Audience
Register

Why Attend

Animal Health Investment Europe is a premier investment forum showcasing the most exciting investment opportunities in animal health and nutrition and connecting those businesses with financial investors and strategic corporate partners.

To complement our investment pitches, we host CEO-level discussions that address the trends and market dynamics of the animal health industry, across all species.

A key element of the investment forum is the full use of a our 1-on-1 private meeting platform, available to all attendees.

Going forward, as the industry experiences a shift towards the detection and prevention of disease, we are increasingly focused on presenting innovation in nutritional health, data analytics, sensors and diagnostics.

This year, for the first time, we will be categorising our presenting companies according to the level of investment they’re seeking, early, mid and late stage.

Animal Health Innovation, Innovative Solutions in...

500+
Attendees
1300+
1-to-1 Meetings
150+
Start-ups
24
Emerging Companies Presenting
40+
Private Meetings per person

Innovation Showcase

Two Showcases Opportunities Available for 2019: A total of 24 start-ups, hand-picked by the Selection Committee, introduce themselves and their products/services on the main stage, in a quick-fire round of presentations.

Animal Health Innovation Showcase
– 12 Companies will be selected to present
Animal Nutrition Innovation Showcase
– 12 Companies will be selected to present

Each showcase will be split into three sessions to introduce start-ups to the best-fit investor for them.

The first round will be open to Pre-Revenue and Pre-Series B companies seeking up to £2 million; the second to Series B+ companies pitching for £2-10 million; and the third to Late-Stage companies looking for investment of £10 million+

 
Applications have now closed for 2019 - Good luck to everyone that has applied!
Finalists announced: 9th January 2019

Presenters will be from the following categories:

Health:
  • Pet Health and Medical
  • Genetics
  • Vaccines, Robotics, Automation
  • Data Analytics & Sensors
  • Diagnostics
  • Medicines

Nutrition:
  • Pet Nutrition and Wellness
  • Immunostimulants
  • Oral vaccines
  • Microbiome peptides
  • Insect protein
  • Bacterial Phages

-----

Congratulations to all 12 Finalists from 2018, especially to our two Runners Up - N2 Pharmaceuticals and Askel Healthcare Ltd. and the Winners of the 2018 Innovation Award - BunyaVax.

Please click the "Presenter Profiles" PDF below to learn more about the twelve most exciting innovations in animal health from 2018...

Resources

Download Resource

We need some information to know where to send the link and how to address our email to you. Please note, a link to the PDF will also become immediately available once this form is submitted.

To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.

Highlights from the Series

Highlights from Animal Health Innovation Europe 2018

Advisory Board

Clinton Lewis

Clinton Lewis Executive Vice President, President, International Operations
ZOETIS

Joachim Hasenmaier

Member of the Board of Managing Directors
BOEHRINGER INGELHEIM

Dirk Ehle

Head of Bayer Animal Health
Bayer

George Gunn

Founder and CEO
Stonehaven Consulting AG

Linda Rhodes

VMD, PhD

Aaron Schacht

Vice President - Global Research and Development
Elanco

Alan Mackay

Executive Partner and Founder
GHO Capital

Dr. James Lloyd

Dean of the College and Professor
University of Florida, Colleague of Veterinary Medicine

Sébastien Huron

Chairman of the Executive Board
Virbac Santé Animale

Selection Committee

Charles Hoare

Head of European Healthcare M&A
Stifel

Matthias Hofer

Partner
Stonehaven Consulting Group

Julia Stephanus

Founder and President
Avviare

Michael Hemprich

Head of Business Development
IDT-Biologika

Maarten Goossens

Co-founder and Principal
Anterra Capital

Martijn Adorf

Managing Partner
Terra Nova Life Sciences b.v.

Oliver Hardcastle

Junior Partner
Stonehaven Consulting

Jarne Ellenholm

Managing Partner
Copenhagen Life Science Advisors

Paul Dick

President
Paul Dick & Associates Ltd

Isaac Fraynd

Dealflow Manager
Aqua-Spark

Venue

200 Aldersgate, St. Pauls, London EC1A 4HD

200 Aldersgate, venue for Animal Health Innovation Europe, London

ACCOMMODATION

Grange St. Paul’s Hotel

10 Godliman Street, London, EC4V 5AJ    (0.6 miles from 200 Aldersgate)
To book a room please email: [email protected]
Book online: http://www.grangehotels.com/business/kisaco-allocation/
Or call Reservations: + 44 (0) 207 074 1000

Sunday 24th Feb £99.00 includes VAT & Continental breakfast
Monday 25th Feb £229.00 includes VAT & Continental breakfast
Tuesday 26th Feb  £279.00 includes VAT & Continental breakfast

Quote Group ID 240219B when booking
Please book by 27 January 2019

 

Thistle City Barbican Hotel

120 Central St, London EC1V 8DS    (0.8 miles from 200 Aldersgate)
Rate per night: £135.00 including VAT & English breakfast
To book a room please call reservations: +44 (0) 800 330 8002 (Option 1)
Email: [email protected]

Quote block code GA1L240219 when booking
Please book by 27 January 2019

 

Crowne Plaza London The City

19 New Bridge St, London EC4V 6DB   (0.8 mile from 200 Aldersgate)
Sunday 24th February £209 inc VAT and English breakfast
Mon 25th & Tues 26th February £289 inc VAT & English breakfast

Book online: here
Call reservations  + 44 (0) 207 438 8040
email: [email protected]

Quote ‘allocation code ‘GA2’ when booking
Please book by 13 January 2019

 

Holiday Inn London Whitechapel

5 Cavell Street, London, E1 2BP   (1.9 miles from 200 Aldersgate)
Sunday 24th Feb  £99 inc VAT and full English breakfast
Monday 25th Feb  £129 inc VAT & full English breakfast
Tuesday 26th Feb  £189 inc VAT and full English Breakfast

Book online at:     GA1 Kisaco
Call reservations  +44(0) 207 791 9013

Quote block code ‘GA3’ when booking
Please book by 27 January 2019

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

Sunday, November 18, 2018 to Saturday, December 15, 2018
Emerging Pass
£899 + VAT
Early Bird rate until 14 Dec (Standard price £999)
Contact [email protected] to book at this rate
Pre-revenue companies
Companies up to £10 Million in annual revenue
Owners of veterinary practices
Academics
Charities
Angel and Venture Capital Investors
Please note: Those offering consultancy or market intelligence services do not qualify for this rate
Sunday, November 18, 2018 to Saturday, December 15, 2018
Delegate Pass
£1,599 + VAT
Early Bird rate until 14 Dec (Standard price £1,799)
Health and Nutrition companies (under £100m in annual revenue)
Digital & Tech Companies
Biotech Companies
Sunday, November 18, 2018 to Saturday, December 15, 2018
Multinational Pass
£2,299 + VAT
Early Bird rate until 14 Dec (Standard price £2,599)
Health and Nutrition Companies over £100m in annual revenue
Saturday, November 17, 2018 to Saturday, December 15, 2018
Service Provider Pass
£2,299 + VAT
Early Bird rate until 14 Dec (Standard price £2,599)
CROs & CMOs
Consultants, M&A Advisors
Private Equity Investors & Brokers
Start-Up Incubators & Accelerators
Vet Service Companies
Preparing registration...
Payment Terms for Animal Health Investment Europe:
  • Please note that a £49 processing fee will apply to any invoices requested.
  • Any questions about your registration, please call +44 (0)20 3696 2920 or email us at [email protected].
  • All Prices are in GBP
  • All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
  • No discounts or offers can be combined.
  • Please view our Cancellation Policy.
  • Emerging Companies are defined as early to mid-stage animal health pharmaceutical or biotech companies that are actively seeking financial investment or product licensing/acquisition. They must be engaged with this company on a full time basis. Those offering consultancy or market intelligence services do not qualify for this rate.
  • Please Note: No additional discounts are available on ‘Emerging Company’ pricing.

The Speakers

 

Joachim Hasenmaier

Member of the Board of Managing Directors
BOEHRINGER INGELHEIM

Joachim Hasenmaier, born 1960 in Vaihingen/Enz, Germany, DVM., is Member of the Board of Managing Directors of C.H. Boehringer Sohn AG & Co. KG since October 1, 2012, responsible for the Corporate Board Division Consumer Health Care and Animal Health. His nationality is German.

Joachim Hasenmaier

Member of the Board of Managing Directors
BOEHRINGER INGELHEIM

Joachim Hasenmaier, born 1960 in Vaihingen/Enz, Germany, DVM., is Member of the Board of Managing Directors of C.H. Boehringer Sohn AG & Co. KG since October 1, 2012, responsible for the Corporate Board Division Consumer Health Care and Animal Health. His nationality is German.

He received a veterinary medical degree (DVM) in 1986 from Ludwig-Maximilians-University, Munich, where he entered into a microbiological research program until 1989 receiving his Doktor med. vet. (PhD) degree. He completed his education with a Master in Management from Kellogg Business School, Chicago, USA in 1991. Prior to joining BI he worked in various positions for various international companies in Germany, Japan, Mexico and Brazil.

In 2002 he joined Boehringer Ingeheim as Corporate Senior Vice President for Boehringer Ingelheim Animal Health. In 2011 he took over the regional responsibilty for Prescription Medicine in NECAR (UK/Ireland, Nordics, Benelux, Canada, Australia/New Zealand). He held this position until he became Member of the Board of Managing Directors at C.H. Boehringer Sohn AG & Co. KG in October 2012.

 

Krijn de Nood

Cultured Meat Expert

Krijn de Nood

Cultured Meat Expert
 

Barney Kay

Head of Agriculture
Tesco

Barney Kay

Head of Agriculture
Tesco
 

Clinton Lewis

Clinton Lewis Executive Vice President, President, International Operations
ZOETIS

Clint Lewis is executive vice president and president of International Operations at Zoetis. In this role, he oversees the management of the livestock and companion animal business markets outside the United States.
Mr. Lewis previously served as president, U.S. Operations at Zoetis and in the Pfizer Animal Health organization. He joined Pfizer Animal Health in 2007.

Clinton Lewis

Clinton Lewis Executive Vice President, President, International Operations
ZOETIS

Clint Lewis is executive vice president and president of International Operations at Zoetis. In this role, he oversees the management of the livestock and companion animal business markets outside the United States.
Mr. Lewis previously served as president, U.S. Operations at Zoetis and in the Pfizer Animal Health organization. He joined Pfizer Animal Health in 2007.

Mr. Lewis joined Pfizer in 1988 as a sales representative in Long Island, N.Y., and has held positions of increasing responsibility in several areas across various commercial operations dedicated to human health prior to joining animal health, including vice president and general manager of Pfizer’s U.S. Anti-Infectives/HIV business unit.

In 2011, Mr. Lewis was elected chairman of the Animal Health Institute (AHI) for the 2011-12 term. A member of AHI since 2007, Mr. Lewis previously served as AHI vice chair for the 2009-2010 term. AHI is the trade association for the animal health industry in the U.S. advocating on various issues important to the industry, including efficient and effective regulatory and approval processes by the U.S. Department of Agriculture (USDA), the Food and Drug Administration (FDA), and the Environmental Protection Agency (EPA).

Mr. Lewis holds a bachelor’s degree in biology from Fairfield University and a Master of Business Administration in marketing from Fairleigh Dickinson University.

 

Jeff Simmons

CEO
Elanco

Jeff Simmons

CEO
Elanco
 

Simon Innes

Chief Executive
CVS Group

Simon was appointed as Chief Executive in January 2004. Prior to this he was Chief Executive of Vision Express from 2000 to 2004, over which time he built the business up to £220m turnover and 205 practices, and reversed a loss-making position to create one of the most profitable corporate optical operators in the UK. The growth strategy that was successful at Vision Express is now being implemented in the veterinary industry by CVS.

Simon Innes

Chief Executive
CVS Group

Simon was appointed as Chief Executive in January 2004. Prior to this he was Chief Executive of Vision Express from 2000 to 2004, over which time he built the business up to £220m turnover and 205 practices, and reversed a loss-making position to create one of the most profitable corporate optical operators in the UK. The growth strategy that was successful at Vision Express is now being implemented in the veterinary industry by CVS.

Prior to Vision Express, Simon was on the board of Hamleys PLC as Operations Director and gained 10 years’ management experience at Marks & Spencer. He also served seven years in the British Army, achieving the rank of Captain in the Royal Engineers.

 

David Hunt

Co-Founder and CEO
Cainthus

David Hunt

Co-Founder and CEO
Cainthus
 

Oliver Hardcastle

Junior Partner
Stonehaven Consulting

Oliver Hardcastle is a business consultant with global experience in the Pharmaceutical sector. He previously spent 7 years working for Novartis, holding a broad range of positions in the Animal Health Division including roles in European Key Account Management, Global Brand Management and Strategic Planning. He went on to support Integration Planning in the sale of Novartis Animal Health to Eli Lilly & Co, Elanco Animal Health where he continued as an Operations Consultant in the Elanco Integration Management Office before joining Stonehaven Consulting AG in 2015.

Oliver Hardcastle

Junior Partner
Stonehaven Consulting

Oliver Hardcastle is a business consultant with global experience in the Pharmaceutical sector. He previously spent 7 years working for Novartis, holding a broad range of positions in the Animal Health Division including roles in European Key Account Management, Global Brand Management and Strategic Planning. He went on to support Integration Planning in the sale of Novartis Animal Health to Eli Lilly & Co, Elanco Animal Health where he continued as an Operations Consultant in the Elanco Integration Management Office before joining Stonehaven Consulting AG in 2015. Oliver was made Junior Partner in 2016 and works with a portfolio of international clients to develop leading strategy.

Oliver has a background in science, having started his career working as a Biologist for a Scottish aquaculture company. Originally from Wales, United Kingdom, he holds a Bachelor of Science Degree in Marine Science from the University of Cardiff.

 

Kathy V. Turner

Corporate Vice President, EMEA & Asia Pacific
IDEXX Europe B.V.

Kathy V. Turner

Corporate Vice President, EMEA & Asia Pacific
IDEXX Europe B.V.
 

Mathieu Castex

Animal Nutrition Global R&D Director
Lallemand

Mathieu Castex

Animal Nutrition Global R&D Director
Lallemand
 

Jason Clay

Senior Vice President
World Wildlife Fund

Jason Clay

Senior Vice President
World Wildlife Fund
 

Davide Rossi

CEO
Fitbark

Davide Rossi

CEO
Fitbark
 

James Andrews

CEO and Founder
Felcana

James Andrews

CEO and Founder
Felcana
 

Aaron Schacht

Vice President - Global Research and Development
Elanco

Aaron Schacht

Vice President - Global Research and Development
Elanco
 

Berwyn Clarke

CEO
PBD Biotech

Berwyn Clarke

CEO
PBD Biotech
 

Ferdrik Ullman

CEO
Indical

Ferdrik Ullman

CEO
Indical
 

Joseph Harvey

Editor
Animal Pharm

Joseph Harvey

Editor
Animal Pharm
 

Brian Topper

Managing Director
AmerisourceBergen Animal Health UK

Brian Topper

Managing Director
AmerisourceBergen Animal Health UK
 

Matt Dobbs, ,

CEO
Westpoint

Matt Dobbs, ,

CEO
Westpoint
 

Mark Heffernan

CEO
Stonehaven Incubate

Mark Heffernan

CEO
Stonehaven Incubate
 

Maarten Goossens

Co-founder and Principal
Anterra Capital

Maarten is a Co-founder and Principal at Anterra Capital. He began his investing career as an Analyst within the Rabo Ventures team in 2009 and was primarily responsible for deal sourcing and execution, and portfolio management. 

Prior to joining Rabo Ventures, Maarten was an Analyst in the Rabobank-Rothschild M&A joint venture in London, where he focused on transactions in Food & Agriculture. 

Maarten holds a Masters of Business Administration from the Free University of Amsterdam, and has studied at the London School of Economics.

Maarten Goossens

Co-founder and Principal
Anterra Capital

Maarten is a Co-founder and Principal at Anterra Capital. He began his investing career as an Analyst within the Rabo Ventures team in 2009 and was primarily responsible for deal sourcing and execution, and portfolio management. 

Prior to joining Rabo Ventures, Maarten was an Analyst in the Rabobank-Rothschild M&A joint venture in London, where he focused on transactions in Food & Agriculture. 

Maarten holds a Masters of Business Administration from the Free University of Amsterdam, and has studied at the London School of Economics.

 

Laëtitia Gerbe

Partner for Investments for AVF Fund
Seventure

Laëtitia Gerbe

Partner for Investments for AVF Fund
Seventure
 

Robin Hargreaves

Veterinary Panel Lead
Agria Pet Insurance

Robin Hargreaves

Veterinary Panel Lead
Agria Pet Insurance
 

Peter McCarthy

President, Global Animal Health Group
Henry Schein

Mr. McCarthy is now in his 7th year at Henry Schein, Inc. He is currently the Company's President, Global Animal Health Group, as well as a member of Henry Schein's Executive Management Committee.

Mr. McCarthy oversees Henry Schein's animal health business, which spans 24 countries including the United States, Australia, New Zealand, Canada, China, Malaysia, Brazil and 17 countries in Europe.

Peter McCarthy

President, Global Animal Health Group
Henry Schein

Mr. McCarthy is now in his 7th year at Henry Schein, Inc. He is currently the Company's President, Global Animal Health Group, as well as a member of Henry Schein's Executive Management Committee.

Mr. McCarthy oversees Henry Schein's animal health business, which spans 24 countries including the United States, Australia, New Zealand, Canada, China, Malaysia, Brazil and 17 countries in Europe.

Before assuming his current position, Mr. McCarthy held key roles at Henry Schein with increasing responsibilities, including President, Henry Schein Animal Health, Europe, and President, Henry Schein Animal Health, International.

Prior to joining Henry Schein, Mr. McCarthy worked at Schering-Plough Animal Health (now Merck Animal Health), serving as Senior Director, Global Operations and General Manager, China. Mr. McCarthy also worked at Wyeth/American Cyanamid for 14 years, helping to grow the human pharmaceutical business.

Mr. McCarthy holds a degree in Applied Biology from the University of Hertfordshire in the U.K., and previously has served as a Member of the Board of the International Federation for Animal Health Europe, and the International Association Executive Animal Health Study Center, CEESA, based in Belgium. Mr. McCarthy is also a graduate and member of the Chartered Institute of Marketing (CIM), which is located in the U.K.

 

Alan Mackay

Executive Partner and Founder
GHO Capital

Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014.

Alan Mackay

Executive Partner and Founder
GHO Capital

Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He is Chair of the BVCA for 2016 – 2017 and previously chaired its Responsible Investment Advisory Board.

 

Marcel Lacaze

Principal
Permira

Marcel joined Permira as a Principal in 2014 and focuses on the healthcare sector. Prior to joining Permira, Marcel worked for Novartis, leading the M&A activities for Novartis Consumer Health, Vaccines & Diagnostics. Before that, he spent eight years in investment banking working for Lazard and Merrill Lynch. Marcel holds degrees in Business Administration, Economics and languages from the University of Passau, Germany, as well as Bejing Yuyan Xueyan, China.

Marcel Lacaze

Principal
Permira

Marcel joined Permira as a Principal in 2014 and focuses on the healthcare sector. Prior to joining Permira, Marcel worked for Novartis, leading the M&A activities for Novartis Consumer Health, Vaccines & Diagnostics. Before that, he spent eight years in investment banking working for Lazard and Merrill Lynch. Marcel holds degrees in Business Administration, Economics and languages from the University of Passau, Germany, as well as Bejing Yuyan Xueyan, China.

 

Cindy Barnes

CEO
Shepherd Software Inc

Cindy Barnes

CEO
Shepherd Software Inc
 

Roy Stein

CEO
Babelbark

Roy Stein

CEO
Babelbark
 

Antione Hubert

CEO
Ynsect

Antione Hubert

CEO
Ynsect
 

James Millar

CCO
Entocycle

James Millar

CCO
Entocycle
 

Simon Doherty

Junior Vice President
British Veterinary Association

Simon is the Senior Vice-President of the Northern Ireland Branch of the British Veterinary Association (BVA). He is an Honorary Lecturer at Queen’s University Belfast and a trustee of livestock development charity, Send a Cow. Simon graduated from the University of Glasgow Veterinary School in 2000 and his career has spanned general veterinary practice, animal health & welfare policy, diagnostics, research, epizootic disease preparedness and biotechnology; with a specific interest in the design of novel vaccines for food-producing animals.

 

Simon Doherty

Junior Vice President
British Veterinary Association

Simon is the Senior Vice-President of the Northern Ireland Branch of the British Veterinary Association (BVA). He is an Honorary Lecturer at Queen’s University Belfast and a trustee of livestock development charity, Send a Cow. Simon graduated from the University of Glasgow Veterinary School in 2000 and his career has spanned general veterinary practice, animal health & welfare policy, diagnostics, research, epizootic disease preparedness and biotechnology; with a specific interest in the design of novel vaccines for food-producing animals.

 

Simon is the Animal Science Specialist for the Agri-Tech Organisation of UK Trade & Investment (UKTI). Using his broad knowledge of the animal health sector, coupled with an understanding of the UK Agri-Tech offer, Simon works with animal health companies – from SMEs to large multinationals – to maximise their opportunities by locating in the UK. In addition to technologies linked to livestock, his portfolio also includes companion animal and aquaculture innovation.

 

 

Jo Malone

CEO
Vet Partners

Jo Malone

CEO
Vet Partners
 

David Perin

CEO
First Vet

David Perin

CEO
First Vet
 

Linda Rhodes

VMD, PhD

Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Linda Rhodes

VMD, PhD

Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.

 

Jean-Louis Hunault

Secretary Général
Diagnostics For Animals

Jean-Louis Hunault

Secretary Général
Diagnostics For Animals
 

Kay O'Donnell

VP Waltham Centre for Pet Nutrition
Mars Petcare

Kay O'Donnell

VP Waltham Centre for Pet Nutrition
Mars Petcare
 

Eric Garcia

IT & Digital Consultant - Founder
Simply Done Tech Solutions



Eric Garcia

IT & Digital Consultant - Founder
Simply Done Tech Solutions



Become a Sponsor

Kisaco Research provides the much needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

The Agenda

You can download our latest agenda here.

Simply fill in this form and we'll send you a PDF version immediately. We need some information to know where to send the file and how to address our email to you.

Animal Health Investment Europe, cover

Alongside our renowned animal health track, which brings you a showcase of the most exciting investment opportunities and novel technologies in animal health, brand new for 2019 will be a dedicated nutrition investment forum, a veterinary practice track and also a human health partnerintg track.

Download the agenda to learn more...

Dowload the Agenda

We need some information to know where to send the link and how to address our email to you. Please note, a link to the PDF will also become immediately available once this form is submitted.

To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.

Headline Partner

Associate Partners

Senior Event Partners

Consulting Partner

Event Partners

Media Partners

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us

We need some information to know how best to respond to your request below.

To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.